Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(12):865; doi:10.1093/jnci/97.12.865
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Using Microarrays in Predictive Models for Breast Cancer

Data from microarray studies have been used to develop predictive models for treatment outcome in breast cancers. Reid et al. (p. 927) attempted to validate a predictive model for antiestrogen response after tamoxifen treatment that was based on the expression ratio of two genes. They studied an independent cohort of 58 patients with resectable estrogen receptor–positive breast cancer, measured the expression of HOXB13 and IL17BR genes, and assessed the association between their expression and outcome by use of four statistical tests. The authors also applied standard supervised methods to the original microarray dataset and to another independent dataset. They . . . [Full Text of this Article]

EGFR, PKB/Akt, and Glioma Response to Erlotinib

Cost-effectiveness of HPV DNA Testing in European Countries

Age-Related Prevalence of Anal Cancer Precursors

Colorectal Cancer Risk and Meat and Fish Intake

Iron Levels and Risk of Colorectal Adenoma in Women


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?